Greco A M, Gentile M, Di Filippo O, Coppola A
Acta Vitaminol Enzymol. 1982;4(1-2):155-62.
A systematic study of vitamin C blood levels in patients with cancer and an evaluation of their modifications when the patients were orally treated with daily large doses of ascorbic acid (5g/day) have been carried out. For excluding any interference on intestinal vitamin C absorption, all patients with digestive tract cancer have been excluded. Our first results concern 24 lung cancer and 35 bladder cancer patients, operable or not, of different sex and age. The study has shown hypovitaminosis C subclinic conditions for the greater part of subjects: in fact the average haematic rate of ascorbic acid approaches to lower level of physiologic range, appearing very low particularly for the younger patients. Periodic haematic dosages of vitamin C of unoperable and operated patients treated with large doses of ascorbic acid, have shown a rapid increase of its blood concentration which frequently has been very over 1500 micrograms%, the higher level of normal range. These high vitamin haematic levels, generally constant during the time, appear usefull in increasing the defence reactions of the cancerous patient.
我们对癌症患者的维生素C血药浓度进行了系统研究,并评估了患者每日口服大剂量抗坏血酸(5克/天)时其血药浓度的变化。为排除对肠道维生素C吸收的任何干扰,所有消化道癌症患者均被排除。我们的首批研究对象为24例肺癌患者和35例膀胱癌患者,涵盖不同性别和年龄,包括可手术和不可手术的患者。研究表明,大部分受试者存在亚临床维生素C缺乏症:事实上,抗坏血酸的平均血药浓度接近生理范围的下限,尤其是年轻患者的血药浓度非常低。对接受大剂量抗坏血酸治疗的不可手术和已手术患者进行的定期维生素C血药浓度检测显示,其血药浓度迅速升高,经常远超正常范围上限1500微克%。这些高血药浓度水平通常在一段时间内保持稳定,似乎有助于增强癌症患者的防御反应。